• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Kazia Therapeutics Limited

    2/20/26 4:09:37 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $KZIA alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    KAZIA THERAPEUTICS LTD

    (Name of Issuer)


    American Depositary Shares

    (Title of Class of Securities)


    48669G105

    (CUSIP Number)


    02/18/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    48669G105


    1Names of Reporting Persons

    Chernett Jorey
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    1,412,662.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    1,412,662.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,412,662.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    12.46 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    KAZIA THERAPEUTICS LTD
    (b)Address of issuer's principal executive offices:

    Item 2. 
    (a)Name of person filing:

    Jorey Chernett (the "Reporting Person")
    (b)Address or principal business office or, if none, residence:

    The principal business address of the Reporting Person is 6222 Indianwood Trail, Bloomfield Hills, MI 48301.
    (c)Citizenship:

    US.
    (d)Title of class of securities:

    American Depositary Shares
    (e)CUSIP No.:

    48669G105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The aggregate percentage of American Depositary Shares ("ADS") owned by the Reporting Person is based upon 11,335,991 American Depository Shares outstanding as of December 11, 2025 (assuming all outstanding Ordinary Shares were represented by American Depository Shares), as disclosed in the Issuer's Prospectus filed pursuant to Rule 424(b)(3), filed with the U.S. Securities and Exchange Commission (the "SEC") on December 23, 2025. As of the close of business on February 19, 2026, the Reporting Person beneficially owned 1,412,662 ADS.
    (b)Percent of class:

    12.46%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (ii) Shared power to vote or to direct the vote:

    See Cover Pages Items 5-9.

     (iii) Sole power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

     (iv) Shared power to dispose or to direct the disposition of:

    See Cover Pages Items 5-9.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Chernett Jorey
     
    Signature:/s/ Jorey Chernett
    Name/Title:Jorey Chernett
    Date:02/20/2026
    Get the next $KZIA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KZIA

    DatePrice TargetRatingAnalyst
    2/6/2025$3.00Buy
    Maxim Group
    10/14/2021$18.00Buy
    Maxim Group
    More analyst ratings

    $KZIA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

    Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced compelling preclinical and translational data supporting the development of NDL2, a potentially first-in-class protein degrader that is designed to selectively eliminate nuclear PD-L1, a previously unrecognized intracellular driver of immunotherapy resistance and metastatic progression that is not addressed by currently approved PD-1/PD-L1 antibodies. Across multiple preclinical models a

    1/30/26 8:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kazia Therapeutics Reports Encouraging Preliminary Clinical Responses in Ongoing Phase 1b Study of Paxalisib in Late-Stage Metastatic Triple-Negative Breast Cancer

    SYDNEY, Jan. 27, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA), today provided a clinical update from its ongoing Phase 1b study evaluating paxalisib in combination with pembrolizumab and chemotherapy in patients with late-stage (Stage IV), metastatic triple-negative breast cancer (TNBC). To date, three patients with metastatic TNBC treated with paxalisib-based regimens have demonstrated meaningful clinical responses, including two partial responses (PRs) in trial participants and one confirmed complete metabolic response (CR) in a patient treated under an expanded access program. Clinical Highlights 2 of 2 evaluable patients enrolled in the Phase 1b trial achieved partial responses

    1/27/26 8:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End

    SYDNEY, Jan. 8, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ:KZIA) today announced that its Chief Executive Officer, John Friend, MD, will be in San Francisco next week to participate in meetings during the annual J.P. Morgan Healthcare Conference week (JPM Week). During the week, Kazia will connect with existing and prospective institutional investors, sell-side analysts, and strategic collaborators, including both established partners and potential new industry counterparties, as part of ongoing investor relations and business development outreach. "We are entering JPM Week with strong strategic and clinical momentum," said Dr. John Friend, M.D., Chief Executive Officer of Kazia Therap

    1/8/26 9:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Kazia Therapeutics with a new price target

    Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $3.00

    2/6/25 7:53:38 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Kazia Therapeutics with a new price target

    Maxim Group initiated coverage of Kazia Therapeutics with a rating of Buy and set a new price target of $18.00

    10/14/21 8:02:40 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Kazia Therapeutics Limited

    SCHEDULE 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    2/20/26 4:09:37 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    1/27/26 8:25:42 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B3 filed by Kazia Therapeutics Limited

    424B3 - KAZIA THERAPEUTICS LTD (0001075880) (Filer)

    1/27/26 8:23:49 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Leadership Updates

    Live Leadership Updates

    View All

    KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS

    SYDNEY, Jan. 18, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA), an oncology-focused drug development company, is pleased to announce the appointment of pharma industry executive, Mr. Robert Apple to Kazia's Board of the Directors (the "Board") as a Non-Executive Director. Mr. Apple brings more than 25 years of senior leadership experience in the pharma industry to Kazia, including 16 years with Antares Pharma, Inc. ("Antares") as Senior Vice President, Chief Financial Officer and Corporate Secretary, and went on to serve as President and Chief Executive Officer

    1/18/24 7:30:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    KAZIA THERAPEUTICS APPOINTS KAREN KRUMEICH AS CHIEF FINANCIAL OFFICER

    SYDNEY, Dec. 13, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of Karen Krumeich as Chief Financial Officer. In this role, Ms Krumeich will focus on building and maintaining relationships with US investors, on preparing the company for future expansion, and on raising the profile of Kazia in global markets. Ms Krumeich is based in Pennsylvania in the United States and will formally commence work with Kazia in January 2022. Kazia CEO, Dr. James Garner, commented, "

    12/13/21 11:00:00 AM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kazia Therapeutics Appoints John Friend, MD, as Chief Medical Officer

    SYDNEY, Nov. 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ:KZIA, ASX: KZA))), an oncology-focused drug development company, is pleased to announce the appointment of John Friend, MD, as Chief Medical Officer. In this role, Dr. Friend will be responsible for overseeing the development and commercialization of Kazia's pipeline drug candidates, and for collaborating with clinicians and scientists to advance the company's research programs. Dr. Friend is based in New Jersey in the United States. Kazia CEO, Dr. James Garner, commented, "We are delighted to welcome John to the Kazia team. With paxalisib moving rapidly towards potential commercialization, and EVT801 now in the clin

    11/15/21 11:00:00 AM ET
    $CLRB
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $KZIA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

    SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    11/14/24 4:19:36 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Kazia Therapeutics Limited

    SC 13G - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    11/6/24 7:53:45 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kazia Therapeutics Limited

    SC 13G/A - KAZIA THERAPEUTICS LTD (0001075880) (Subject)

    8/12/24 7:28:02 PM ET
    $KZIA
    Biotechnology: Pharmaceutical Preparations
    Health Care